Huntington Study Group Clinical Studies

1
Huntington Study Group Clinical Studies
STUDY NAME N SPONSORED BY Period of Activity
HORIZON (A Phase III, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dimebon in Patients with Mild-To-Moderate Huntington Disease) 350 Medivation, Inc. in collaboration with Pfizer, Inc. 2009-2010
PREQUEL (A Multi-Center, Double-blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE) in PRE-manifest Huntingtons disease) 90 NIH (NINDS) 2009-2010
HART (A Multi-Center, North American, Randomized, Double-Blind, Parallel Group Study Comparing Three Doses Of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease) 220 NeuroSearch Sweden, AB 2008-2010
CREST-E (Creatine Safety, Tolerability, and Efficacy in Huntington's disease) 650 NIH (NCCAM), FDA (Orphan Products Division) 2007-2013
DIMOND B (A Multi-Center, Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Dimebon in Subjects with Huntingtons Disease) 90 Medivation, Inc 2007-2008
2CARE (Coenzyme Q10 (CoQ) in Huntingtons Disease) 608 NIH (NINDS) 2006-2011
COHORT (Cooperative Huntingtons Disease Observational Research Trial) 3500 High Q Foundation/CHDI 2006-Unlimited
2
Huntington Study Group Clinical Studies
STUDY NAME N SPONSORED BY Period of Activity
DIMOND A (A Multi-Center, Phase 1-2a, Open-Label, Dosage-Escalation Study of Dimebon in Subjects with Huntingtons Disease) 9 Medivation, Inc. 2006-2007
RESPOND (An Examination of Responses to Potential Discrimination from Individuals at Risk for HD) 375 NIH (NHGRI) 2005-2008
PHEND-HD (Phenylbutyrate Development for Huntingtons Disease) 60 NIH (NINDS), HP Therapeutics Foundation, Inc. 2005-2007
DOMINO (A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntingtons Disease) 100 FDA (Orphan Drug Division) 2005-2008
TREND-HD (A Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion) in Subjects with Mild to Moderate Huntington's Disease) 316 Amarin Neurosciences, Ltd. 2004-2008
TETRA-HD (A Randomized Double-Blind, Placebo Controlled Study of Tetrabenazine in Patients with Huntingtons Chorea) 84 Prestwick Pharmaceuticals, Inc. 2003-2004
QuBE (Coenzyme Q10 (Ubiquinone) Bioequivalence Study) 24 High Q Foundation/CHDI 2003-2005
Pre-2CARE (Pilot Safety and Tolerability Study of Coenzyme Q10 in Huntingtons Disease and in Normal Subjects) 30 High Q Foundation/CHDI 2003-2004
3
Huntington Study Group Clinical Studies
STUDY NAME N SPONSORED BY Period of Activity
TETRA-OLHD (An Open-Label, up to 80 week extension Study of Tetrabenazine, for the treatment of Huntingtons Chorea) 75 Prestwick Pharmaceuticals, Inc. 2003-2007
PREDICT-HD (Neurobiological Predictors of Huntingtons Disease ) 1022 NIH (NINDS), HIGH Q Foundation/CHDI 2002-2013
MINO (Minocycline Dosing and Safety in Huntingtons Disease) 63 FDA (Orphan Drug Division), HDSA, HDF 2001-2003
RID-HD (RIluzole Dosing in Huntingtons Disease) 63 FDA (Orphan Drug Division) 1999-2001
Creatine (Pilot Study using Creatine in Patients with Huntingtons Disease) 50 HDSA 1999-2004
PHAROS (Prospective Huntington At Risk Observational Study) 1001 NIH (NHGRI, NINDS), High Q Foundation/CHDI 1998-2010
CARE-HD (Co-Enzyme Q10 And Remacemide Evaluation in HD) 347 NIH (NINDS) 1997-2002
INTRO-HD (INvestigation of Tolerability in a Randomized Trial of OPC 14-117 in HD) 64 Otsuka American Pharmaceuticals, Inc. 1994-1996
UHDRS (Unified Huntingtons Disease Rating Scale (UHDRS 99) 5576 Huntington Study Group 1993-2006
START-HD (Short Term Assessment of Remacemide Tolerability HD) 30 Fisons Pharmaceuticals, Inc. 1993-1994